Ability of the VITEK 2 advanced expert system to identify β-lactam phenotypes in isolates of Enterobacteriaceae and Pseudomonas aeruginosa

被引:54
|
作者
Sanders, CC
Peyret, M
Moland, ES
Shubert, C
Thomson, KS
Boeufgras, JM
Sanders, WE
机构
[1] Creighton Univ, Ctr Res Anti Infect & Biotechnol, Sch Med, Dept Med Microbiol & Immunol, Omaha, NE 68178 USA
[2] BioMerieux Inc, Hazelwood, MO 63042 USA
[3] BioMerieux, LaBalme Les Grottes, France
关键词
D O I
10.1128/JCM.38.2.570-574.2000
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Advanced Expert System (AES) was used in conjunction with the VITEK 2 automated antimicrobial susceptibility test system to ascertain the p-lactam phenotypes of 196 isolates of the family Enterobacteriaeae and the species Pseudomonas aeruginosa. These isolates represented a panel of strains that had been collected from laboratories worldwide and whose beta-lactam phenotypes had been characterized by biochemical and molecular techniques. The antimicrobial susceptibility of each isolate tvas determined with the VITEK 2 instrument, and the results were analyzed with the AES to ascertain the beta-lactam phenotype. The results were then compared to the beta-lactam resistance mechanism determined by biochemical and molecular techniques. Overall, the AES was able to ascertain a beta-lactam phenotype for 183 of the 196 (93.4%) isolates tested. For 111 of these 183 (60.7%) isolates, the correct beta-lactam phenotype was identified definitively in a single choice by the AES, while for an additional 46 isolates (25.1%), the AES identified the correct beta-lactam phenotype provisionally within two or more choices. For the remaining 26 isolates (14.2%), the beta-lactam phenotype identified by the AES was incorrect. However, for a number of these isolates, the error nas due to remediable problems. These results suggest that the AES is capable of accurate identification of the beta-lactam phenotypes of gram-negative isolates and that certain modifications can improve its performance even further.
引用
收藏
页码:570 / 574
页数:5
相关论文
共 40 条
  • [21] IN-VITRO ACTIVITY OF 5 BETA-LACTAM/BETA-LACTAMASE INHIBITOR COMBINATIONS AGAINST CONSECUTIVE ISOLATES OF THE ENTEROBACTERIACEAE AND PSEUDOMONAS-AERUGINOSA
    MCLAUGHLIN, JC
    BARRY, AL
    FUCHS, PC
    GERLACH, EH
    HARDY, DJ
    PFALLER, MA
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1994, 33 (02) : 223 - 230
  • [22] Accuracy of three automated systems (MicroScan WalkAway, VITEK, and VITEK 2) for susceptibility testing of Pseudomonas aeruginosa against five broad-spectrum beta-lactam agents
    Sader, HS
    Fritsche, TR
    Jones, RN
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (03) : 1101 - 1104
  • [23] Multicenter Evaluation of Ceftazidime-Avibactam Susceptibility Testing of Enterobacterales and Pseudomonas aeruginosa on the Vitek 2 System
    Humphries, Romney
    Campeau, Shelley
    Davis, Thomas E.
    Nagaro, Kristin J.
    LaBombardi, Vincent J.
    Franklin, Simone
    Heimbach, Lisa
    Dwivedi, Hari P.
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2021, 59 (03)
  • [24] Detection of low-level resistance to carbapenems using the VITEK 2 and the advanced expert system
    Afkou, Z.
    Kontopoulou, K.
    Sofianou, D.
    Tsivitanidou, M.
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S464 - S465
  • [25] Validation of the VITEK2 and the Advance Expert System with a collection of Enterobacteriaceae harboring extended spectrum or inhibitor resistant β-lactamases
    Cantón, R
    Pérez-Vázquez, M
    Oliver, A
    Coque, TM
    Loza, E
    Ponz, F
    Baquero, F
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2001, 41 (1-2) : 65 - 70
  • [26] Multicentre evaluation of the VITEK 2 Advanced Expert System for interpretive reading of antimicrobial resistance tests
    Livermore, DM
    Struelens, M
    Amorim, J
    Baquero, F
    Bille, J
    Canton, R
    Henning, S
    Gatermann, S
    Marchese, A
    Mittermayer, H
    Nonhoff, C
    Oakton, KJ
    Praplan, F
    Ramos, H
    Schito, GC
    Van Eldere, J
    Verhaegen, J
    Verhoef, J
    Visser, MR
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (02) : 289 - 300
  • [27] Potential impact of the VITEK 2 system and the advanced expert system on the clinical laboratory of a university-based hospital
    Sanders, CC
    Peyret, M
    Moland, ES
    Cavalieri, SJ
    Shubert, C
    Thomson, KS
    Boeufgras, JM
    Sanders, WE
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (07) : 2379 - 2385
  • [28] Evaluation of VITEK 2 for analysis of Enterobacteriaceae using the Advanced Expert System (AES) versus interpretive susceptibility guidelines used at Dynacare Kasper Medical Laboratories, Edmonton, Alberta
    Blondel-Hill, E
    Hetchler, C
    Andrews, D
    Lapointe, L
    [J]. CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (11) : 1091 - 1103
  • [29] Synergistic action of phospholipase a2 and beta-lactam antibiotics against Pseudomonas aeruginosa cystic fibrosis isolates
    Dubouix, A
    Campanac, C
    Roques, C
    Salles, JP
    Chap, H
    Chabanon, G
    Marty, N
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 : S203 - S203
  • [30] Assessment of the In Vitro Activities of Ceftolozane/Tazobactam and Ceftazidime/Avibactam in a Collection of Beta-Lactam-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Clinical Isolates at Montpellier University Hospital, France
    Viala, Benjamin
    Zaidi, Fatma Zohra
    Bastide, Mathilda
    Dumont, Yann
    Le Moing, Vincent
    Jean-Pierre, Helene
    Godreuil, Sylvain
    [J]. MICROBIAL DRUG RESISTANCE, 2019, 25 (09) : 1325 - 1329